Latest news with #CPFT
Yahoo
6 days ago
- Business
- Yahoo
More funding 'unlikely' for mental health trust
Health bosses at an NHS trust say they are unlikely to get "significant increases" in funding to tackle growing waiting lists. The Cambridgeshire and Peterborough NHS Foundation Trust's (CPFT) board of directors heard this week that there were "significant waiting lists" of ADHD and autism referrals. As of 8 April, there were 9,757 patients on the ADHD and autism waiting list, with a mean average wait of 92 weeks, the trust's board of directors heard. Dr Mike Knapton, non-executive director and quality and safety committee chair, said the trust took waiting lists "very seriously" and said there are "a number of pieces of work" looking at addressing the situation. The CPFT delivers many NHS services that are provided in the community, including physical and mental health, and specialist services. The trust also runs the Cavell Centre in Peterborough, and Fulbourn Hospital in Cambridge. In December, the NHS trust was rated as "requires improvement" for its mental health services for adults of working age. It said at the time that it took the findings of the Care Quality Commission (CQC) "very seriously". The trust's overall rating with the CQC was "good". The report said the ADHD service "continues to be extremely pressured" and that there was "inadequate resource for the demand". Holly Sutherland, chief operating officer, said given the context of NHS finances the trust is "unlikely to get significant increases in funding" to address the increasing demand for services. She said the trust was looking at how it could "transform delivery" to be efficient and get to those who were most in need. Eileen Milner, chair at the trust, said there had been "exceptional growth" in referrals for autism and ADHD. She added that it was a national issue and told the board that she had recently met with chairs at other NHS Trusts, who had shared that they are experiencing the same increases in demand for services. Ms Milner said they heard from a NHS England representative at this meeting, but said she did not believe a national strategy to address the issue was well developed at this stage. Follow Peterborough news on BBC Sounds, Facebook, Instagram and X. Mental health waiting lists 'grow considerably' Mental health crisis service needs improvement Health bosses concerned over mental health delays Cambridgeshire and Peterborough NHS Foundation Trust
BBC News
6 days ago
- Business
- BBC News
Funding rise unlikely for Cambridgeshire's mental health trust
Health bosses at an NHS trust say they are unlikely to get "significant increases" in funding to tackle growing waiting Cambridgeshire and Peterborough NHS Foundation Trust's (CPFT) board of directors heard this week that there were "significant waiting lists" of ADHD and autism of 8 April, there were 9,757 patients on the ADHD and autism waiting list, with a mean average wait of 92 weeks, the trust's board of directors Mike Knapton, non-executive director and quality and safety committee chair, said the trust took waiting lists "very seriously" and said there are "a number of pieces of work" looking at addressing the situation. The CPFT delivers many NHS services that are provided in the community, including physical and mental health, and specialist trust also runs the Cavell Centre in Peterborough, and Fulbourn Hospital in Cambridge. In December, the NHS trust was rated as "requires improvement" for its mental health services for adults of working age. It said at the time that it took the findings of the Care Quality Commission (CQC) "very seriously".The trust's overall rating with the CQC was "good".The report said the ADHD service "continues to be extremely pressured" and that there was "inadequate resource for the demand".Holly Sutherland, chief operating officer, said given the context of NHS finances the trust is "unlikely to get significant increases in funding" to address the increasing demand for said the trust was looking at how it could "transform delivery" to be efficient and get to those who were most in Milner, chair at the trust, said there had been "exceptional growth" in referrals for autism and added that it was a national issue and told the board that she had recently met with chairs at other NHS Trusts, who had shared that they are experiencing the same increases in demand for Milner said they heard from a NHS England representative at this meeting, but said she did not believe a national strategy to address the issue was well developed at this stage. Follow Peterborough news on BBC Sounds, Facebook, Instagram and X.
BBC News
26-05-2025
- Health
- BBC News
Mental health patient treated with clozapine via virtual ward
An NHS hospital trust has said it could be the first in England to have treated a patient with an anti-psychotic medication while monitoring them mental health trust for Cambridgeshire and Peterborough said it treated the patient for schizophrenia with the drug were being monitored via a so-called virtual ward, where clinicians in the hospital keep track of the patient while they are at Dr Rajeev Krishnadas said the patient was "doing very well". The treatment was the result of a partnership between the Cambridgeshire and Peterborough NHS Foundation Trust (CPFT) - which oversees mental health services in the area - and the North West Anglia NHS Foundation Trust (NWAFT).Dr Krishnadas, from CPFT, said clozapine was "hugely under-prescribed" because it was usually difficult to monitor the patient after they had begun treatment."If this initial project continues to be a success, even more people will be able to access clozapine and get the help and support they need," he Deyo Okubadejo, clinical director for virtual wards at NWAFT, said: "This may also release some capacity for other patients who require urgent admission to a mental health ward from home or from an emergency department." Mixed success Virtual wards make use of video and other technology, such as wearable a patient receiving clozapine would need to stay in scheme was first trialled at Peterborough City Hospital in Health Foundation charity has pointed to the mixed success of virtual wards, with some areas struggling to access the right technology and one study finding that these "beds" could cost twice as much as a real hospital NHS describes psychosis as when people lose some contact with might involve seeing or hearing things that other people cannot see or hear – hallucinations - and believing things that are not actually true, known as delusions. Follow Peterborough news on BBC Sounds, Facebook, Instagram and X.
Powys County Times
23-04-2025
- Health
- Powys County Times
Blood test trial offers ‘exciting new era in cancer detection'
A blood test that can detect cancer before symptoms develop is being assessed for potential NHS use, health officials have said. Health Secretary Wes Streeting will announce that the Government is backing the next phase of testing for a groundbreaking blood test which can detect 12 cancers, including bowel cancer. Speaking at an event to mark the renaming of a cancer lab in memory of the late Dame Deborah James, Mr Streeting said the work will help to bring England's cancer survival rates 'back up to some of the best in the world'. April is #BowelCancer Awareness Month Do you know the symptoms of bowel cancer? It is important to see your doctor if you have any symptoms of bowel cancer for 3 weeks or more. Learn more: — CPFT (@CPFT_NHS) April 22, 2025 'Dame Deborah James dedicated her life to raising awareness for cancer and finding ways that we can beat it, so it is only right that we honour her legacy by investing in research to help stop one of the country's biggest killers,' Mr Streeting said. Dame Deborah died of bowel cancer aged 40 in 2022. Officials from the Department of Health and Social Care (DHSC) said that the Bowelbabe Laboratory at the Francis Crick Institute in London, which is funded by Cancer Research UK, will bring together leading scientists and will conduct 'cutting-edge' research. The department also said that patients, including those with bowel cancer, could soon benefit from the test. The miONCO-Dx blood test could lead to more cancers being detected at an earlier stage, which means treatments will be more effective, officials added. The technology, made by biotechnology company Xgenera, was developed alongside scientists from the University of Southampton. It works by examining the microRNA in a blood sample and uses AI to identify if cancer is present and if so, where it is located in the body. Initial tests show the blood test can detect up to 12 common cancers – including lung, gastric, prostate, oesophageal, liver, bladder, ovarian, bowel, pancreatic and breast cancers as well as bone and soft tissue sarcoma and a type of brain tumour – and has high sensitivity, with 99% accuracy. It was developed using data from 20,000 patients. The technology is to be trialled in 8,000 patients thanks to a £2.4 million grant though the National Institute for Health and Care Research (NIHR) and the Government. The DHSC said that the development of the test has moved onto the next phase, the 'verification and validation phase', which will look at collating evidence to support the approval of the test for use in the NHS. Mr Streeting, who had cancer himself in 2021, added: 'We know that the key to surviving cancer is catching it as early as possible, so this government is taking the urgent action needed to make sure that happens through our plan for change, from developing world-leading technology to detect bowel cancer earlier, through to setting up hubs for the UK's top scientists to research and treat the disease. 'And research is only one part of the work we're doing. Our national cancer plan will transform cancer so patients can get the latest treatments and technology, ultimately bringing this country's cancer survival rates back up to some of the best in the world.' Professor Lucy Chappell, chief scientific adviser at the DHSC and chief executive of the NIHR, added: 'Innovations such as the miONCO-Dx blood test offer an exciting new era in cancer detection with the potential for quicker, easier and more effective ways to detect cancers before they become more difficult to treat.' Professor Sir Stephen Powis, NHS England's national medical director, said: 'This blood test has the potential to help us detect bowel cancer earlier and reduce the need for invasive tests, and the next step in this trial will now be vital in gathering further evidence on its effectiveness and how it could work in practice. 'Dame Deborah James was a tireless and inspirational campaigner who helped change the national conversation on bowel cancer – it's fitting that this lab in her name will drive forward research that could help thousands more people survive the disease.' Michelle Mitchell, chief executive of Cancer Research UK, added: 'Bowel cancer is the second biggest cause of cancer deaths in the UK. I'm delighted to welcome the Health Secretary, Wes Streeting, to the Bowelbabe Laboratory and show him the cutting-edge research being carried out in the name of the inspirational Dame Deborah James. She touched the lives of so many, and her legacy is supporting people affected by bowel cancer across the country.
The Herald Scotland
23-04-2025
- Health
- The Herald Scotland
Blood test trial offers ‘exciting new era in cancer detection'
Speaking at an event to mark the renaming of a cancer lab in memory of the late Dame Deborah James, Mr Streeting said the work will help to bring England's cancer survival rates 'back up to some of the best in the world'. April is #BowelCancer Awareness Month Do you know the symptoms of bowel cancer? It is important to see your doctor if you have any symptoms of bowel cancer for 3 weeks or more. Learn more: — CPFT (@CPFT_NHS) April 22, 2025 'Dame Deborah James dedicated her life to raising awareness for cancer and finding ways that we can beat it, so it is only right that we honour her legacy by investing in research to help stop one of the country's biggest killers,' Mr Streeting said. Dame Deborah died of bowel cancer aged 40 in 2022. Officials from the Department of Health and Social Care (DHSC) said that the Bowelbabe Laboratory at the Francis Crick Institute in London, which is funded by Cancer Research UK, will bring together leading scientists and will conduct 'cutting-edge' research. The department also said that patients, including those with bowel cancer, could soon benefit from the test. The miONCO-Dx blood test could lead to more cancers being detected at an earlier stage, which means treatments will be more effective, officials added. The technology, made by biotechnology company Xgenera, was developed alongside scientists from the University of Southampton. It works by examining the microRNA in a blood sample and uses AI to identify if cancer is present and if so, where it is located in the body. Initial tests show the blood test can detect up to 12 common cancers – including lung, gastric, prostate, oesophageal, liver, bladder, ovarian, bowel, pancreatic and breast cancers as well as bone and soft tissue sarcoma and a type of brain tumour – and has high sensitivity, with 99% accuracy. It was developed using data from 20,000 patients. The technology is to be trialled in 8,000 patients thanks to a £2.4 million grant though the National Institute for Health and Care Research (NIHR) and the Government. The DHSC said that the development of the test has moved onto the next phase, the 'verification and validation phase', which will look at collating evidence to support the approval of the test for use in the NHS. Mr Streeting, who had cancer himself in 2021, added: 'We know that the key to surviving cancer is catching it as early as possible, so this government is taking the urgent action needed to make sure that happens through our plan for change, from developing world-leading technology to detect bowel cancer earlier, through to setting up hubs for the UK's top scientists to research and treat the disease. 'And research is only one part of the work we're doing. Our national cancer plan will transform cancer so patients can get the latest treatments and technology, ultimately bringing this country's cancer survival rates back up to some of the best in the world.' Professor Lucy Chappell, chief scientific adviser at the DHSC and chief executive of the NIHR, added: 'Innovations such as the miONCO-Dx blood test offer an exciting new era in cancer detection with the potential for quicker, easier and more effective ways to detect cancers before they become more difficult to treat.' Professor Sir Stephen Powis, NHS England's national medical director, said: 'This blood test has the potential to help us detect bowel cancer earlier and reduce the need for invasive tests, and the next step in this trial will now be vital in gathering further evidence on its effectiveness and how it could work in practice. 'Dame Deborah James was a tireless and inspirational campaigner who helped change the national conversation on bowel cancer – it's fitting that this lab in her name will drive forward research that could help thousands more people survive the disease.' Michelle Mitchell, chief executive of Cancer Research UK, added: 'Bowel cancer is the second biggest cause of cancer deaths in the UK. I'm delighted to welcome the Health Secretary, Wes Streeting, to the Bowelbabe Laboratory and show him the cutting-edge research being carried out in the name of the inspirational Dame Deborah James. She touched the lives of so many, and her legacy is supporting people affected by bowel cancer across the country.
